Latest / Pharmacy Podcast Network / Key Factors Impacting MolDX® Coverage Determinations and Reimbursement with Dr. Megan Landsverk, Scientific Director, MolDX® and Chief Scien
Transcript
- 0:00Speaker 1: This episode is brought to you by Thermo Fisher Scientific.
- 0:03Speaker 1: Go from treat and wait to test and tailor. Use
- 0:06Speaker 1: genetic testing to research how to help patients get the
- 0:09Speaker 1: right medication dose for them at the right time the
- 0:12Speaker 1: first time. Pharmacogenomics or PGX has the potential to help
- 0:17Speaker 1: reduce healthcare costs and help protect lives. Physicians and pharmacists
- 0:21Speaker 1: can support the movement to integrate PGX into the standard
- 0:24Speaker 1: of care so patients can get tailored treatment with fewer
- 0:27Speaker 1: adverse reactions. Thermo Fisher Scientific has been helping to drive
- 0:31Speaker 1: PGX research for over a decade, and we continue to
- 0:34Speaker 1: invest and participate in collaborations to help make it accessible
- 0:38Speaker 1: and affordable. Explore pharmacogenomics at ThermoFisher dot com slash PGX Education.
- 0:50Speaker 2: You are listening to the global network of podcasters dedicated
- 0:53Speaker 2: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 1:12Speaker 3: In a world where one size fits all medications dominate
- 1:16Speaker 3: the pharmaceutical industry, precision medicine brings a ray of hope
- 1:19Speaker 3: for those seeking customized healthcare. Pharmacists have a unique opportunity
- 1:23Speaker 3: to help people in need of specialized testing to ensure
- 1:26Speaker 3: medications work is intended. Welcome to Precision Help in PGX,
- 1:31Speaker 3: where we unravel the wonders of precision medicine and its
- 1:34Speaker 3: potential to revolutionize the way we approach pharmacy care. Get
- 1:38Speaker 3: ready to uncover the secrets behind pharmacogenomics and how it's
- 1:42Speaker 3: transforming lives one genome amount of time.
- 1:53Speaker 4: I'm your host, doctor Becky Winslow, and you're listening to
- 1:56Speaker 4: the Precision Health and PGX podcast. In case you're wondering
- 2:00Speaker 4: what happened to the PGX for Pharmacist podcasts, you're actually
- 2:04Speaker 4: listening to it right now, only with a different name.
- 2:07Speaker 4: With a go to broaden our listenership and content to
- 2:10Speaker 4: include non pharmacogenomics based precision health topics. My co host,
- 2:15Speaker 4: doctor Banas Serami, and I decided to rebrand the podcast
- 2:20Speaker 4: and no different than we did on the PGX for
- 2:22Speaker 4: Pharmacist podcasts. We'll continue to explore all things pharmacogenomics related,
- 2:27Speaker 4: including pharmacist roles in PGX, and our mission still includes
- 2:32Speaker 4: educating and advocating for PGX and we're going to continue
- 2:36Speaker 4: to accomplish this mission through exclusive interviews with highly qualified
- 2:41Speaker 4: and well experienced industry leaders such as today's special guests.
- 2:47Speaker 5: I can't begin to tell you, guys how.
- 2:49Speaker 4: Excited I am about today's special guests. This podcast episode
- 2:53Speaker 4: has been long in the making, and you, guys, you're
- 3:01Speaker 4: really going to take on some great information from this episode.
- 3:05Speaker 4: Our special guest for today is doctor Meghan Lansford. She's
- 3:09Speaker 4: a scientific director at Moldix and Chief Science Officer at
- 3:14Speaker 4: Palmetto GBA.
- 3:16Speaker 5: So welcome to the podcast, Megan.
- 3:19Speaker 6: We're so fortunate to have you join us today.
- 3:21Speaker 4: Can you please introduce yourself to our audience so they
- 3:24Speaker 4: can appreciate your expertise on today's topic, key factors that
- 3:29Speaker 4: impact MODIX covers, determinations and reimbursement.
- 3:33Speaker 7: Awesome, Well, happy to be here, Becky. You make it
- 3:36Speaker 7: make me sound really fancy. I swear I'm not that fancy.
- 3:41Speaker 7: So yeah, So as Becky, As you mentioned, I have
- 3:46Speaker 7: been with Palmetto GBA and the Moldex program for about
- 3:49Speaker 7: four years now. Prior to joining the program, I was
- 3:54Speaker 7: a laboratory director in a variety of different laboratories that
- 3:59Speaker 7: perform germline constitutional testing, somatic testing, and pharmacogenetics. On my background,
- 4:06Speaker 7: I have a PhD in biochemistry and molecular biology and
- 4:11Speaker 7: got my ABMGG board certification in molecular genetics quite a
- 4:16Speaker 7: while ago. We won't talk about how long ago. From
- 4:20Speaker 7: a pharmacogenetics standpoint, I was one of the founding members
- 4:25Speaker 7: of the imagenetics program in the Soup Fall South Dakota
- 4:30Speaker 7: Sanford Healthcare System, where we did pharmacogenetic testing within the
- 4:35Speaker 7: laboratory within the healthcare system there, and we're I think
- 4:39Speaker 7: one of the first laboratories to be able to seamlessly
- 4:41Speaker 7: integrate those results back into the electronic medical record for
- 4:45Speaker 7: decision support for our physicians. So have seen quite a
- 4:49Speaker 7: bit of pharmacogenetics come and go, and I'm excited to
- 4:54Speaker 7: be in a role now that's a bit different from
- 4:57Speaker 7: the laboratory roles that I've had in the past, and
- 5:00Speaker 7: happy to join you today to talk about it.
- 5:03Speaker 4: Well, I find your background very impressive. Whether you think
- 5:07Speaker 4: it is.
- 5:10Speaker 7: The data all trades, that's that's the thing on.
- 5:14Speaker 4: So yeah, thank you for introducing yourself. I want to
- 5:17Speaker 4: jump right into our discussion so we have time to
- 5:20Speaker 4: share as much as possible with our audience. Needless to say,
- 5:24Speaker 4: in my consulting questions surrounding Mouldix, Palmetto GBA for pharmacogenomics.
- 5:31Speaker 4: So probably i'd say at least soventy five percent of
- 5:34Speaker 4: the questions that I feel.
- 5:36Speaker 5: So let's start by having you define.
- 5:39Speaker 4: Palmetto GBAS and the MOULDIX program's purpose.
- 5:45Speaker 7: Oh sure, So PALMETOGBA is a Medicare contractor, and so
- 5:49Speaker 7: what you know you sort of hear is Medicare pace
- 5:53Speaker 7: for all sorts of services and sets of criteria and
- 5:56Speaker 7: coverage for what types of services that they'll pay for. However,
- 6:00Speaker 7: the funding doesn't necessarily come from Medicare. And y'all can't
- 6:03Speaker 7: see my air quotes here, but I'm doing my air quotes.
- 6:06Speaker 4: There are a.
- 6:07Speaker 7: Number of different contractors that issue coverage, determination policies and
- 6:14Speaker 7: criteria for how Medicare would pay for those services across
- 6:17Speaker 7: the country, and each one of them is a little
- 6:20Speaker 7: bit different, and that's what Palmetto is. So PALMETOGBA is
- 6:24Speaker 7: a Medicare contractor that pays for Medicare claims on behalf
- 6:30Speaker 7: of Medicare. Now, mold X is a program that was
- 6:35Speaker 7: established under the Palmetto GBA business because there was an
- 6:43Speaker 7: acknowledgment this was gosh, I want to say, twenty eleven
- 6:48Speaker 7: more than almost fifteen years ago that molecular diagnostic services
- 6:52Speaker 7: are very complicated, they're specialized, and they wanted to bring
- 6:55Speaker 7: in subject matter expertise for those particular types of service.
- 7:00Speaker 7: So even though the Moldex program was born at Palmetto GBA,
- 7:05Speaker 7: we now work with a number of other Medicare contractors
- 7:09Speaker 7: as well, so not just Palmetto, but uh Nridian, WPS
- 7:14Speaker 7: and CGS, so that when we set criteria for the
- 7:18Speaker 7: types of services that we would pay for under the
- 7:21Speaker 7: Medicare umbrella, all of those other Medicare contractors do the
- 7:25Speaker 7: same thing. So you don't just have to be in
- 7:27Speaker 7: a Palmeto jurisdiction to be in a Moldex jurisdiction. Any
- 7:32Speaker 7: of those other MAP contractors have the same types of
- 7:36Speaker 7: policies that Palmetto does.
- 7:39Speaker 4: I'm glad you pointed that out because indeed the clarity
- 7:44Speaker 4: needed to be to put out there because there is
- 7:47Speaker 4: questions about okay, am I in a MOLDIX or am
- 7:50Speaker 4: I not in a MOLDIX? So yes, thanks for clarifying
- 7:55Speaker 4: that information. So, now that we've defined the mission, can
- 8:00Speaker 4: you define the role of the DECKS Diagnostic Exchange in
- 8:06Speaker 4: relationship to the MODI X program, and then absolutely then.
- 8:11Speaker 6: We'll jump into the technical assessments purpose.
- 8:15Speaker 7: Sure, And so I think at this point too, it
- 8:17Speaker 7: would be good to point out that PALMETOGBA also does
- 8:21Speaker 7: services for non non medicare commercial providers as part of
- 8:27Speaker 7: the DECK program, and so it kind of we're sort
- 8:30Speaker 7: of ever growing, right. So it started off with moldex
- 8:34Speaker 7: at just Palmeto. Now it's moldex at other macs across
- 8:39Speaker 7: the country. Now the DECKS Exchange, which I'll talk about
- 8:42Speaker 7: it in just a sec also includes services for commercial
- 8:47Speaker 7: providers as well. And the reason we do all of
- 8:49Speaker 7: this is if you sort of think back to how
- 8:53Speaker 7: services were coded pre twenty thirteen. And I'm dating all
- 8:57Speaker 7: of us again, so any of you remember, you know
- 8:59Speaker 7: what we went through in twenty thirteen. It was a
- 9:01Speaker 7: very painful experience, right where prior to twenty thirteen, molecular
- 9:06Speaker 7: services were essentially coded on the methodology. So say if
- 9:09Speaker 7: you're doing a Sanger sequencing test, it was individual PCR
- 9:13Speaker 7: bits and pieces were all sort of stacked up. They
- 9:16Speaker 7: were all methodology codes, and nobody really knew how many
- 9:21Speaker 7: bits and pieces went into each gene. The payers had
- 9:25Speaker 7: no exposure into the types of services that were performed.
- 9:29Speaker 7: Who's doing what. There was a lot of discourse across
- 9:33Speaker 7: all of the different laboratories who may be submitting codes
- 9:36Speaker 7: for the same service. So in twenty thirteen, we kind
- 9:41Speaker 7: of changed the entire CPT code system on its head
- 9:46Speaker 7: and CPT codes were now assigned per gene and so
- 9:52Speaker 7: most of your listeners are probably familiar with we've got
- 9:54Speaker 7: tier one codes and Tier two codes, and those Tier
- 9:58Speaker 7: one codes are sort of a gene by gene basis.
- 10:01Speaker 7: We have now ones for panels and larger things, but
- 10:04Speaker 7: back then it was one gene one code. And as
- 10:09Speaker 7: the code system has grown over time, and as the
- 10:12Speaker 7: technology has grown over time, the technology has really out
- 10:16Speaker 7: pieced the code set that we're working with from twenty
- 10:21Speaker 7: thirteen right. And so the problem is is that payers
- 10:25Speaker 7: now don't have the clarity of that, you know, of
- 10:30Speaker 7: a one gene one code system. So that is sort
- 10:34Speaker 7: of why the DEX catalog was created. So in the
- 10:37Speaker 7: DEX Catalog, what we do is we assign another unique
- 10:42Speaker 7: identifier that is unique to our program. So it's called
- 10:46Speaker 7: the Z code, and so every test in our system
- 10:50Speaker 7: gets its own unique Z code, and that way we
- 10:54Speaker 7: have an identifier that says this specific test is this
- 10:59Speaker 7: specific set of genes or single genes or whatever it is,
- 11:03Speaker 7: and it comes from this specific live for this specific reason.
- 11:07Speaker 7: So the DECKS catalog gives us a level of specificity
- 11:11Speaker 7: that we don't get out of some of the CPT
- 11:15Speaker 7: code sets and gives us that clarity for services that
- 11:19Speaker 7: the laboratories are providing.
- 11:21Speaker 6: So basically it provides transparency for the payer so that
- 11:25Speaker 6: they know what they're paying for right absolutely, which is important. Yeah, so.
- 11:34Speaker 4: You know, can definitely understand why payers would want to
- 11:37Speaker 4: know what they're paying for.
- 11:39Speaker 6: So in line with that, how does.
- 11:42Speaker 4: The technical assessment play, you know, how does it fit
- 11:47Speaker 4: into the picture with the tests, the Z code and
- 11:52Speaker 4: payers understanding.
- 11:53Speaker 6: What they're paying for?
- 11:56Speaker 7: Sure? So one of the things that you know, the
- 11:58Speaker 7: payers really want to know, right is not only what
- 12:02Speaker 7: test was being performed, but was this the right test
- 12:06Speaker 7: on the right patient for the right reasons?
- 12:08Speaker 4: Right?
- 12:09Speaker 7: What are we paying for? And so when we do
- 12:12Speaker 7: technical assessments, and you'll hear you'll hear it from our
- 12:14Speaker 7: team over and over again, we really harp on what
- 12:18Speaker 7: is the intended use of the test, what is the
- 12:22Speaker 7: intended use patient population? Or this service, who are you
- 12:27Speaker 7: going to test this on? And so when folks submit
- 12:31Speaker 7: tests to the DEX system, I think of it's sort
- 12:33Speaker 7: of like a library. So if you think of Dex's
- 12:35Speaker 7: catalog like a library, the laboratories are the ones that
- 12:39Speaker 7: are writing the books. They're you know, they've they're putting
- 12:43Speaker 7: all of that information into the book. And the payers
- 12:46Speaker 7: are the ones that can come to us and check
- 12:48Speaker 7: out the books and they say, well, we want to
- 12:50Speaker 7: see what the contents are. So our technical assessments are
- 12:54Speaker 7: sort of equivocal to being an editor for the payers.
- 12:59Speaker 7: So when they admit their books to us, you know,
- 13:02Speaker 7: you have to go through and make sure that it
- 13:03Speaker 7: does the book have page numbers? Did you actually put
- 13:06Speaker 7: a title on your book? Is it you know, are
- 13:09Speaker 7: the chapters in the right order? And so when you
- 13:12Speaker 7: hear a technical assessment, as far as DEX is concerned,
- 13:16Speaker 7: that's really what our team is doing. They are looking
- 13:19Speaker 7: at the service to say, you know, is this service
- 13:22Speaker 7: being performed on the right type of patient? Does this
- 13:26Speaker 7: service have all of the things necessary as you know,
- 13:30Speaker 7: based on guidelines, recommendations, and other criteria that it really
- 13:34Speaker 7: should have to be performed on that patient, Are you
- 13:38Speaker 7: using an appropriate methodology and so all of those things.
- 13:42Speaker 7: So as part of the technical assessment, we go through
- 13:45Speaker 7: everything around that service. But the good news is is
- 13:48Speaker 7: that once you pass a technical assessment and it is successful,
- 13:53Speaker 7: you're kind of done. You're you know, once you've demonstrated
- 13:57Speaker 7: that you're ready to go if you use that service, well,
- 14:01Speaker 7: we're only going to do that technical assessment one time
- 14:04Speaker 7: if you pass, If you.
- 14:06Speaker 6: Don't got to kind of come back to the story. Yes, yes, absolutely, yeah.
- 14:12Speaker 4: So in my experience supporting PGX labs with Multix technical assessments,
- 14:18Speaker 4: Multix often does not approve a lab test technical assessment
- 14:22Speaker 4: due to the test panel design.
- 14:24Speaker 6: So, for example, a.
- 14:26Speaker 4: Lab may include a diagnostic gene and PGX genes in
- 14:31Speaker 4: the same panel, or the intended population like you mentioned
- 14:35Speaker 4: for the panel doesn't.
- 14:37Speaker 6: Align with the panel.
- 14:39Speaker 4: Now I've seen labs not include all gene variants with
- 14:43Speaker 4: non clinical significance at will as well. And while I
- 14:49Speaker 4: perceive Moldix policies to be clear and concise about what
- 14:53Speaker 4: you guys expect in a PGX test, I see labs
- 14:56Speaker 4: struggle with this. So would you say my experience is
- 15:00Speaker 4: anecdotal or common or.
- 15:03Speaker 7: I would yeah, I would think it's probably more common
- 15:07Speaker 7: than than not until last sort of understands conceptually how
- 15:11Speaker 7: MOLDEX thinks. If you look at our policies and the
- 15:16Speaker 7: way the MOLDEX policies are, there's sort of two definitions
- 15:20Speaker 7: of the testing. There are single gene tests and there
- 15:24Speaker 7: are multi gene panels. And once you go over a one,
- 15:29Speaker 7: you're in panel territory, so you're either doing a single
- 15:32Speaker 7: gene or a panel. The way we look at panels
- 15:36Speaker 7: is that as long as your panel has the minimum
- 15:41Speaker 7: number of genes for a particular intended use, if you
- 15:46Speaker 7: add extra genes, that's okay. However, we're not going to
- 15:50Speaker 7: pay you for those extra genes. I'm going to reimverse
- 15:53Speaker 7: you for those extra genes. But we also look at
- 15:56Speaker 7: it from a standpoint of are the extra genes and
- 15:59Speaker 7: beararience that you're including going to potentially cause harm to
- 16:04Speaker 7: those patients? And I know it's a little bit arbitrary,
- 16:07Speaker 7: right how one defines causing harm, But say, for example,
- 16:13Speaker 7: a laboratory includes a gene on their pharmacogenetics panel that
- 16:20Speaker 7: doesn't necessarily have guidelines from sort of our professionally accepted
- 16:26Speaker 7: groups such as the Clinical Pharmacogenetic Interpretation Consortium. I'm just
- 16:31Speaker 7: going to call them seepic, so CEPICK or FDA, et cetera.
- 16:35Speaker 7: You know, somebody published a paper last year. They think
- 16:38Speaker 7: it's great, but the evidence just isn't there. If a
- 16:42Speaker 7: physician is going to change a patient's drug dosing or
- 16:47Speaker 7: drug that they're on based on that level of evidence,
- 16:51Speaker 7: it could potentially cause harm in that patient. So you're,
- 16:57Speaker 7: you know, listeners need to be really cognizant of would
- 17:02Speaker 7: somebody make a change to this patient's medical management based
- 17:06Speaker 7: on these results and has the evidence really been defined
- 17:10Speaker 7: for making that change, because you could be inadvertently altering
- 17:15Speaker 7: the medical management of that patient, not in a good way.
- 17:19Speaker 6: I absolutely agree.
- 17:20Speaker 4: As a matter of fact, when I'm helping labs differentiate
- 17:23Speaker 4: themselves from others, you know, when they're promoting their test
- 17:27Speaker 4: to prescribers of the tests, that's one thing I teach
- 17:31Speaker 4: them to point out to the prescriber is that our
- 17:34Speaker 4: test only includes drugging payers with you know, high clinical
- 17:38Speaker 4: utility evidence, and that's less risky for the the prescriber
- 17:43Speaker 4: who's using the test and the patient whose outcomes are
- 17:46Speaker 4: dependent on the So yeah, that's that's critical information for
- 17:51Speaker 4: everybody to understand.
- 17:54Speaker 7: Could not agree more about you. I would say too
- 17:57Speaker 7: that you know, for for your the folks that are
- 18:00Speaker 7: running these types of services, and you know you always
- 18:03Speaker 7: put limitations at the end of your report. However, just
- 18:09Speaker 7: putting a limitation at the end of the report or saying,
- 18:12Speaker 7: you know, physicians should be making decisions on their own,
- 18:16Speaker 7: even from sort of a cap clear you know, oversight,
- 18:21Speaker 7: it doesn't absolve the laboratory and the director of the
- 18:25Speaker 7: laboratory whose name is on that report. You know, you're
- 18:30Speaker 7: you are one hundred percent responsible for the results that
- 18:32Speaker 7: are that are in that report, whether you know you
- 18:35Speaker 7: try to cave it away or not at the end.
- 18:37Speaker 7: And so I would say always keep that in mind
- 18:40Speaker 7: that you know you're you are one hundred percent responsible
- 18:44Speaker 7: for the results that that you are giving back to providers.
- 18:48Speaker 4: Yeah, great point. I mean, because labs will say to me,
- 18:51Speaker 4: but the but the physician wants us to include this
- 18:55Speaker 4: drug gene pairent. Well, you know, we can't give them
- 18:59Speaker 4: what they want if it's a good endangered patients. I mean,
- 19:01Speaker 4: it's just quite that simple, you know, Like you said,
- 19:07Speaker 4: if there's one paper that supports the association, then that's
- 19:10Speaker 4: not the type of information.
- 19:12Speaker 6: We want them acting on.
- 19:14Speaker 4: So yeah, good, let's elaborate on and maybe walk through
- 19:21Speaker 4: some steps that labs can take to avoid some of
- 19:24Speaker 4: the most common errors in clinical PGX tests reporting that
- 19:30Speaker 4: results in MDIX not as, such as the post genotype translations,
- 19:39Speaker 4: avoiding the red, yellow, and green stoplight visual.
- 19:44Speaker 7: And also.
- 19:46Speaker 4: You know, like we just mentioned, not reporting clinical annotations
- 19:51Speaker 4: for non C pick A and B drug gene pairs.
- 19:55Speaker 8: Yeah, so I think the way our team sort of
- 19:58Speaker 8: does deserve us for pharmacogenetic testing, you can you can
- 20:02Speaker 8: easily break it down into sort of three parts and
- 20:04Speaker 8: three sections.
- 20:06Speaker 7: So we've got the wet bench part, which is the genotyping,
- 20:09Speaker 7: which tends to be sort of I hate to say
- 20:11Speaker 7: it's the theiest part, but it's you know, it is
- 20:16Speaker 7: the assay. You know, laboratory should be really thoughtful about
- 20:19Speaker 7: what you know, genes and alleles are are on that assay.
- 20:23Speaker 7: But what we tend to look for there is, you know,
- 20:27Speaker 7: not only can you get uh consistent results that not say,
- 20:32Speaker 7: you know, the samples that you received from choreel or
- 20:34Speaker 7: well established samples, but laboratories really need to demonstrate that
- 20:39Speaker 7: they can take a sample that they're getting in their
- 20:42Speaker 7: laboratory from end to end, and that is it's something
- 20:46Speaker 7: that I think we a technical assessment is not successful. Uh,
- 20:51Speaker 7: I don't want to say often, but it is something
- 20:53Speaker 7: that that happens a lot where you have to you
- 20:57Speaker 7: have to do more than just test corel sample. Our
- 21:00Speaker 7: folks really want to see that you as a laboratory
- 21:04Speaker 7: can get a sample, extract the DNA, get the DNA
- 21:09Speaker 7: through your assay, and get consistent, reproducible routine results out
- 21:14Speaker 7: the back end, which also means that you have to
- 21:18Speaker 7: run things more than once, right, And so you know,
- 21:22Speaker 7: we as a laboratory field, as a whole, we all
- 21:24Speaker 7: have to make sure that you know when you put
- 21:27Speaker 7: a sample on the machine and run that assay, that
- 21:29Speaker 7: the results are going to be the same, you know,
- 21:32Speaker 7: the first time, the one hundredth time, the one thousandth
- 21:35Speaker 7: time you run that assay, they shiny consistent. The middle
- 21:39Speaker 7: part I hate. I don't want to use the word bioinformatics,
- 21:42Speaker 7: so you know, we could, but because that's like a
- 21:44Speaker 7: next generation sequencing thing, but it's sort of very similar
- 21:47Speaker 7: to the bioinformatics. What one might call it dry bench
- 21:51Speaker 7: part of it. And this can be done locally or
- 21:55Speaker 7: by you know, a secondary a vendor or a secondary laby.
- 22:00Speaker 7: It's becoming very routine in the field for one lab
- 22:04Speaker 7: to do the wet bench part and another lab to
- 22:06Speaker 7: do the dry bench part. However, that's the translational part, right,
- 22:11Speaker 7: So once you get your genotyping, now you have to
- 22:14Speaker 7: show that that genotype to star allele to haplotype to
- 22:19Speaker 7: metabolizer status process is again consistent, routine and robust. And
- 22:27Speaker 7: you know, I know that you know, the labs that
- 22:29Speaker 7: you work with probably say yes, but we're working with
- 22:32Speaker 7: so and so and they've done this at bazillion times.
- 22:36Speaker 7: But there's always things you have to validate, right the
- 22:40Speaker 7: data transfer to them, the data transfer back, ensuring that
- 22:45Speaker 7: these the results are always consistent and routine, and there
- 22:50Speaker 7: should be a demonstration of that process. You know, I
- 22:54Speaker 7: can tell you I remember, you know, when we started
- 22:57Speaker 7: doing these results way back when when I worked at Sanford,
- 23:02Speaker 7: we actually had our entire team sitting in a room
- 23:05Speaker 7: and I would hit finalize on my end and we
- 23:09Speaker 7: would watch it go from me to our laboratory. Bioinformatics folks,
- 23:14Speaker 7: to make sure they tracked it all the way through,
- 23:17Speaker 7: and then they transferred it off to our EMR Bioinformatics
- 23:20Speaker 7: IT people and they tracked it all the way through,
- 23:23Speaker 7: and then it went all the way to a report.
- 23:25Speaker 7: And we did that over and over and over again
- 23:28Speaker 7: until we could ensure that that process wasn't going to fail.
- 23:33Speaker 7: So that's kind of the middle part, and we were
- 23:36Speaker 7: missing that a lot in our submissions. Just a demonstration
- 23:41Speaker 7: of where the data is going. And then the reporting piece, right,
- 23:45Speaker 7: because whether or not a laboratory is doing the reporting
- 23:50Speaker 7: in house or they're using an external vendor, as we
- 23:54Speaker 7: just talked about, you as a laboratory are one hundred
- 23:57Speaker 7: percent responsible for what's in that report. And so you're
- 24:02Speaker 7: you know, you're not off the hook if you say, well,
- 24:04Speaker 7: we sent it off to this know, this other vendor
- 24:07Speaker 7: and they're doing all the work for us and sending
- 24:10Speaker 7: it back. And that's kind of a piece that that's
- 24:14Speaker 7: probably the piece that we send unsuccessful technical assessments back
- 24:18Speaker 7: for the most is are you aware of what is
- 24:22Speaker 7: going into your report? And are you uh is that
- 24:28Speaker 7: report containing information that meets MOLDEX policy. And so our
- 24:34Speaker 7: policies say that the the evidence and the gene drug
- 24:40Speaker 7: relationships have to be clinically actionable as defined by f
- 24:46Speaker 7: DA or c PIG. So if you start putting all
- 24:48Speaker 7: sorts of other stuff in there, our reviewers are going
- 24:51Speaker 7: to see it and there that's the first thing that
- 24:53Speaker 7: they're going to ping on on on the reports.
- 24:57Speaker 4: And I've seen those reviews and I concur when I
- 25:04Speaker 4: get called in after the first technical assessment failure and
- 25:08Speaker 4: I read those follow ups, yes, you know, when I
- 25:11Speaker 4: did not have the opportunity to intervene before the technical
- 25:14Speaker 4: assessment was submitted. Yes, I concur that is what you
- 25:20Speaker 4: guys say. So, and I think this speaks to you know,
- 25:26Speaker 4: if your laboratory doesn't have someone in house that we
- 25:31Speaker 4: would deem a PGX expert on these individual buckets that
- 25:38Speaker 4: you just described, it's critical that they consult with someone
- 25:43Speaker 4: that is because it costs less money to get it
- 25:47Speaker 4: correct on the front end than it does to probably
- 25:50Speaker 4: try to fix it on the back end.
- 25:52Speaker 6: So yeah, that.
- 25:55Speaker 7: Is a great point, Becky, And I think having individuals
- 26:00Speaker 7: with pharmacogenetics expertise involved from the very beginnion is crucial, right,
- 26:07Speaker 7: because these types of services are unique, you know, Pharmacogenetics
- 26:14Speaker 7: is a field in and of itself for a reason.
- 26:18Speaker 7: There it's the only field that uses star illegal nomenclature
- 26:23Speaker 7: and metabolizer status nomenclature, and there's a lot of things
- 26:27Speaker 7: that are very specific to the field, and one needs
- 26:30Speaker 7: to have a knowledge of the types of drugs that
- 26:33Speaker 7: are being reported and the types of interactions, and so
- 26:37Speaker 7: you know, if laboratories are looking at and doing pharmacogenetic
- 26:40Speaker 7: testing and getting involved, I wouldn't recommend more to bring
- 26:45Speaker 7: in someone with pharmacogenetics expertise to help them through that
- 26:51Speaker 7: process and even stay with them through that process to
- 26:53Speaker 7: ensure that what they are giving back to the patients
- 26:58Speaker 7: is really an appropriate, great report that the physicians can use.
- 27:02Speaker 4: Absolutely absolutely, Yeah, we could do a whole episode on
- 27:06Speaker 4: that topic.
- 27:07Speaker 6: Will save that.
- 27:10Speaker 9: Yeah, I mean, it's it's it's when I mean when
- 27:13Speaker 9: I when I got into it, you know, I I
- 27:16Speaker 9: had a little bit of pharmacogenetics expertise from my fellowship
- 27:19Speaker 9: training and things like that. But it's it's not it's
- 27:23Speaker 9: not easy as much as you know some folks out
- 27:26Speaker 9: there would like to say that it's easy and you
- 27:28Speaker 9: just put your sample on the machine and.
- 27:29Speaker 7: Get your report. It's much more complicated than that, And
- 27:33Speaker 7: and education across the board for for physician end users
- 27:38Speaker 7: and laboratories is really important. Absolutely.
- 27:43Speaker 6: I mean, it's not unlike any other m.
- 27:50Speaker 4: You know, comprehensive, complex novel test that's out there.
- 27:56Speaker 6: It has to have the support to make it success full.
- 28:00Speaker 4: And I think that's what we're trying to drive home
- 28:02Speaker 4: here is providing those that support to help make it possible.
- 28:09Speaker 4: So we've got a couple of other topics. I want
- 28:12Speaker 4: to make sure we're able to touch on them today
- 28:15Speaker 4: as well. So let's transition from educating our audience about
- 28:20Speaker 4: the PGX test panel and the reporting design to educating
- 28:24Speaker 4: them on an equally important factor that's critical to PGX
- 28:28Speaker 4: Testing's financial sustainability, and that is common claim submission errors.
- 28:35Speaker 4: So can you share with our audience Multix's expectations for
- 28:40Speaker 4: laboratories submitting PGX test claims for reimbursements, such as including
- 28:45Speaker 4: the drug of interest on the claim.
- 28:48Speaker 7: Store is That's a great question. I'm Becky, So what
- 28:54Speaker 7: what I think the best thing to remind listeners and
- 28:58Speaker 7: folks that are doing pharmacoaching out testing, especially if you're
- 29:01Speaker 7: going to submit to Medicare is that Medicare pays for
- 29:06Speaker 7: services for individuals who I don't want to say have
- 29:12Speaker 7: something wrong, but we don't pay for screening services. There
- 29:16Speaker 7: has to be a reason for the service to be performed,
- 29:21Speaker 7: and that reason can't be we want to run this
- 29:24Speaker 7: panel on somebody just in case at some point in
- 29:26Speaker 7: time in the future they may or may not need
- 29:29Speaker 7: to go on plavix. Right, your patients need to have
- 29:33Speaker 7: some sort of treatment being considered or treatment is being
- 29:40Speaker 7: changed to meet coverage criteria for Medicare right now. A
- 29:49Speaker 7: lot of the Medicare services that the laboratories may be
- 29:52Speaker 7: familiar with, right, we use diagnosis codes for that. So
- 29:55Speaker 7: ICD nines and ICD tens where your individual has a
- 29:59Speaker 7: diagnosed of cancer X and they say, okay, so you've
- 30:03Speaker 7: got this type of cancer, We're going to run this
- 30:06Speaker 7: particular test and they match up, and that makes sense
- 30:10Speaker 7: from a pharmacogenetics standpoint. It's really difficult to match up
- 30:14Speaker 7: ICD ten diagnosis codes to an individual who's getting tested,
- 30:18Speaker 7: say for polypharmacy, right because it could be all sorts
- 30:22Speaker 7: of codes. So what the way we have chosen to
- 30:26Speaker 7: do it is if it is a specialized service for
- 30:30Speaker 7: specific diagnostic intended use, So say for psychiatric services, we
- 30:35Speaker 7: do require specific diagnosis codes for those particular services. However,
- 30:42Speaker 7: if you're in a polypharmacy situation, we want to make
- 30:46Speaker 7: sure that the patient is either going on a drug
- 30:51Speaker 7: or is being considered for a drug or drugs to
- 30:55Speaker 7: essentially justify the panel being run on that patient. We
- 31:00Speaker 7: do require the drug that the patent drug or drugs
- 31:04Speaker 7: that the patient is on or being considered for to
- 31:09Speaker 7: be on the claim to be able to say this
- 31:13Speaker 7: is the service that was performed. This is essentially the
- 31:17Speaker 7: reason that the service was performed. The patient is being
- 31:21Speaker 7: considered for all of these drugs, and our systems are
- 31:24Speaker 7: set up such that those drugs are the ones that
- 31:28Speaker 7: are recommended by SPECK n FDA. So if you have
- 31:33Speaker 7: a panel and your patient is being considered for drugs
- 31:38Speaker 7: that are not on a CPICK or FDA list which
- 31:41Speaker 7: can be found in our billain encoding articles which we
- 31:44Speaker 7: can talk about in a second, but if you include
- 31:47Speaker 7: you could put one hundred genes on that claim. If
- 31:50Speaker 7: they're not relevant guidelines based genes, your claim is going
- 31:55Speaker 7: to get rejected.
- 31:56Speaker 6: Yep.
- 31:57Speaker 4: Well, it makes sense from a farm DSE perspective, absolutely,
- 32:02Speaker 4: because it's drug driven.
- 32:04Speaker 7: It is one hundred percent drug driven, and it's very
- 32:07Speaker 7: different from how all of the other claims processes systems
- 32:10Speaker 7: are work. So we wanted to make sure that it
- 32:15Speaker 7: was pharmacogenetics driven. It was drug driven. And I think
- 32:19Speaker 7: that's a great way to say it that PGX claims
- 32:22Speaker 7: as part of the moldex system are drug driven, not
- 32:27Speaker 7: so much diagnosis code driven.
- 32:28Speaker 4: Right, And I mean that's a very common situation I
- 32:32Speaker 4: run into where the lab says, can you provide me all.
- 32:35Speaker 6: The ICD codes ICD ten codes that will you know.
- 32:40Speaker 4: Correspond with my tests so that we know that the
- 32:43Speaker 4: patient's going to be qualified, And like, well, I can
- 32:46Speaker 4: provide you ICD ten codes that go with the drugs,
- 32:49Speaker 4: but the most critical point is the drug itself. So yes, absolutely,
- 32:57Speaker 4: that is an area of confusion that I was able
- 33:00Speaker 4: to We were able to clear up.
- 33:02Speaker 10: Here is drug first, drug first, absolutely, So very important
- 33:12Speaker 10: to our.
- 33:13Speaker 4: Discussion today, Megan, is how the medical necessity documentation for
- 33:19Speaker 4: clinical PGX tests differs from non PGX tests.
- 33:23Speaker 6: And I think we kind of just touched on it
- 33:26Speaker 6: with the drug driven ordering of.
- 33:28Speaker 4: The test and the need for the test. But you know,
- 33:34Speaker 4: how does medical necessity documentation impact test reimbursement.
- 33:39Speaker 5: I have been on the opposite side post billing in
- 33:44Speaker 5: an audit of.
- 33:45Speaker 4: Claims, and I know what my experiences were from from
- 33:50Speaker 4: that audit experience with a laboratory that did not have
- 33:56Speaker 4: the proper documentation of medical necessity. Could you speak on
- 34:01Speaker 4: medical necessity for Moldix's perspective for pharmacogenemics And you know,
- 34:07Speaker 4: like I said, you've already touched on a few things.
- 34:09Speaker 4: You don't pay for screening tests. It's when the patient
- 34:13Speaker 4: has an adverse reaction or non therapeutic outcome.
- 34:17Speaker 6: You know, if you could elaborate on that, yeah, it
- 34:20Speaker 6: really you know.
- 34:21Speaker 7: As we just discussed talks, It just it goes back
- 34:24Speaker 7: to the drugs, right, and it goes back to is
- 34:27Speaker 7: the patient on a particular drug or is that patient
- 34:30Speaker 7: being considered for a particular drug right now, right, not
- 34:34Speaker 7: ten years in the future, but now, and setting up
- 34:38Speaker 7: your test requisition forms and your order forms for the
- 34:43Speaker 7: physicians to be able to attest to that. You know,
- 34:47Speaker 7: I don't think you know, we don't necessarily need you know,
- 34:52Speaker 7: a huge dump out of the e MR record that
- 34:54Speaker 7: the physician said. But if a test requisition form is
- 34:58Speaker 7: set up such the physicians are filling them out and saying, my,
- 35:04Speaker 7: you know, my patient is they're going into the CAP
- 35:07Speaker 7: lab and I need to know if they should come
- 35:09Speaker 7: out on plavix or brelenta, then you can build your
- 35:13Speaker 7: test requisition forms such that the physicians are a testing
- 35:17Speaker 7: to that, because, you know, the even though the laboratories
- 35:21Speaker 7: are the ones that are submitting the claims for the
- 35:24Speaker 7: service that they're performing, it's the physicians that are ordering
- 35:27Speaker 7: them on the front end, right, So that's where the
- 35:30Speaker 7: medical notes have to come from. And if the laboratories
- 35:34Speaker 7: build their systems out in a way such that they
- 35:37Speaker 7: get all of that information from the physician, you know,
- 35:41Speaker 7: then then you're then you're good, right, So just to
- 35:44Speaker 7: make sure that, however you're interacting with your physician providers,
- 35:48Speaker 7: that they are documenting the reason for ordering the service.
- 35:52Speaker 4: So, Megan, I believe what you're describing is a test
- 35:56Speaker 4: requisition form that captures medical necessity for pharmaca genemics testing.
- 36:01Speaker 4: And that's the type of test requisition form that I
- 36:04Speaker 4: typically designed for the labs I work with. And I
- 36:08Speaker 4: think it's important to point out to our audience that
- 36:12Speaker 4: you know, Medicare has said that that test requisitions can serve.
- 36:15Speaker 6: As medical necessity documentation.
- 36:17Speaker 7: Is that accurate if we have a billing encoding article
- 36:21Speaker 7: and unfortunately I don't know the number off the top
- 36:23Speaker 7: of our head, but we have an article that describes
- 36:27Speaker 7: how the test requisition form I built correctly and has
- 36:31Speaker 7: all the correct information can provide all of the information
- 36:34Speaker 7: that one needs for for claim submission.
- 36:39Speaker 6: Yeah, that's and I think that's very important.
- 36:43Speaker 4: Two, it's a time saving stuff if you know, the
- 36:48Speaker 4: doctor can technically document that medical necessity own that test
- 36:52Speaker 4: requisition form.
- 36:54Speaker 7: So yeah, and that is that is and it is
- 36:56Speaker 7: really important too because you know, as we discussed the
- 37:00Speaker 7: although the laboratories are the ones submitting claims to get paid,
- 37:04Speaker 7: the laboratory is still responsible for ensuring that the right
- 37:09Speaker 7: patient was tested for the right reason, even if it
- 37:12Speaker 7: was a physician that made that decision. And so labs
- 37:15Speaker 7: really need to remember that that whatever that physician is doing,
- 37:19Speaker 7: it does not absolve you of the responsibility of ensuring
- 37:23Speaker 7: accurate testing is being performed for the right reason.
- 37:27Speaker 4: Absolutely, I think we would deem that a laboratory stewardship program. Yes,
- 37:34Speaker 4: I am not a laboratorian from education, but I have
- 37:38Speaker 4: been for the last twelve years.
- 37:40Speaker 6: So laboratory stewardship is critical.
- 37:43Speaker 4: And you know, like, for example, I posted the other
- 37:47Speaker 4: day on LinkedIn about medical necessity documentation for PGX, and
- 37:51Speaker 4: I got a comment that, well, we educate the prescribers
- 37:56Speaker 4: how they should document medical necessity, but sold them to
- 38:01Speaker 4: document it correctly. And I was sent them a private
- 38:05Speaker 4: message saying, actually, you're still on the line. You're you know,
- 38:11Speaker 4: you're still on the hook for that that documentation and
- 38:14Speaker 4: let me tell you how I know. So yeah, I'm
- 38:18Speaker 4: again glad that we're getting this information out there, just
- 38:21Speaker 4: to clarify that indeed the laboratory is ultimately responsible for
- 38:25Speaker 4: submitting medically necessary tests.
- 38:29Speaker 7: So yeah, and at MOULDUX, all we have and we
- 38:32Speaker 7: have five different laboratory or five different medical directors within
- 38:36Speaker 7: the mold US program with the Palmetto and every last
- 38:39Speaker 7: one of us has been a laboratory director in some capacity,
- 38:44Speaker 7: a way or or another, So we understand how difficult
- 38:48Speaker 7: some of those conversations are to have, you know, a
- 38:51Speaker 7: laboratory with the position and you know, the the competition
- 38:56Speaker 7: that well, if I don't do whatever, you know, Doc
- 39:00Speaker 7: Smith says, then he's just going to go on down
- 39:03Speaker 7: to the next lab, and we would hope that the
- 39:05Speaker 7: next lab would also, you know, practice proper laboratory stewardship
- 39:09Speaker 7: and have those same conversations with doctor Smith. So it
- 39:12Speaker 7: is a relationship between the physicians and the laboratories just
- 39:18Speaker 7: to ensure that the physicians know what they're getting and
- 39:21Speaker 7: know what they're ordering and document what they're doing properly,
- 39:25Speaker 7: and that the laboratories also document properly. So it's it
- 39:29Speaker 7: really is a relationship that starts with the physician and
- 39:32Speaker 7: patient interaction through the laboratory, you know, onto the medicare
- 39:40Speaker 7: here and we all have a level of responsibility to
- 39:45Speaker 7: the patient that is at the end of that report.
- 39:47Speaker 4: Absolutely, and in my experience with laboratory stewardship programs, because.
- 39:52Speaker 5: I have set them up for pharmacogenomics and other testing,
- 39:56Speaker 5: is that.
- 39:57Speaker 4: The prescribers are typically very grateful because they don't want
- 40:03Speaker 4: to order non medically necessary tests. They want to order
- 40:08Speaker 4: medically necessary tests and when they value the outcomes that
- 40:13Speaker 4: can result from a PGX test, but you know, maybe
- 40:17Speaker 4: they don't know how medical necessities should be documented. They
- 40:21Speaker 4: appreciate you know, the lab being able to help them
- 40:26Speaker 4: so that their patients, you know, so their patients get
- 40:28Speaker 4: the help that they need, because that's ultimately what it's
- 40:31Speaker 4: all about.
- 40:32Speaker 6: Just like you said, was if you know, if.
- 40:34Speaker 4: A prescriber gets frustrated because they don't know how to
- 40:39Speaker 4: document the medical necessity or they don't know how to
- 40:43Speaker 4: identify patients for testing or stratify them, then they're not
- 40:48Speaker 4: going to order and the patient's ultimately not going to
- 40:51Speaker 4: benefit from the tests. So you know, laboratory stewardship is
- 40:55Speaker 4: not just being the police and saying no, you know,
- 41:00Speaker 4: we're not submitting this claim and you need to get
- 41:03Speaker 4: it right. It's about being that relationship, having that relationship
- 41:07Speaker 4: and that coaching and.
- 41:09Speaker 7: Getting the pharmacists involved back. Yeah, I couldn't stress it more. Right,
- 41:14Speaker 7: If you as a laboratory are not comfortable with pharmacogenetic
- 41:18Speaker 7: results and guidelines, and if you have a physician that's
- 41:22Speaker 7: not necessarily comfortable but wants to get into a program
- 41:26Speaker 7: and to understand, you know, find the folks like yourself,
- 41:31Speaker 7: you know, the pharmacists, the people that can educate and help.
- 41:35Speaker 7: I think you know, education is is everything that that
- 41:41Speaker 7: really helps the physicians to understand what they're you know,
- 41:44Speaker 7: what they're doing, what they're getting, and how to implement it,
- 41:47Speaker 7: as well as laboratories who may not have the experience
- 41:51Speaker 7: in how to interpret the results, et cetera.
- 41:56Speaker 4: And I mean, that's another great point because part of
- 41:58Speaker 4: the investigation that I was involved in, not me personally,
- 42:06Speaker 4: I didn't do anything wrong, but the PGAs claims that
- 42:10Speaker 4: were being investigated. Part of that was that the records
- 42:15Speaker 4: never showed any action on the test results. And in
- 42:20Speaker 4: some circumstances it was because the prescriber didn't know how
- 42:23Speaker 4: to act on the results. In others it was just
- 42:26Speaker 4: you know, it was negligence, you know, they just didn't
- 42:30Speaker 4: get acted on. But so it's not just how to
- 42:34Speaker 4: stratify patients, how to document medical necessity, but how do
- 42:39Speaker 4: I act on those test results? And how do I
- 42:42Speaker 4: document that I that I acted on those test results
- 42:45Speaker 4: are all part of this claim submission medical necessity package,
- 42:52Speaker 4: I guess, or laboratory stewardship package that we're that we're
- 42:55Speaker 4: talking about.
- 42:56Speaker 6: So yeah, that's that's a great point.
- 43:00Speaker 4: So I want to we don't have a lot of
- 43:02Speaker 4: time left, and I want to wrap up with one
- 43:06Speaker 4: suggestion that you've you've made to me and our conversations
- 43:09Speaker 4: in the past, is that one way that clinical laboratories
- 43:14Speaker 4: can support their tests is by collaborating with academic institutions
- 43:19Speaker 4: to help them develop and validate their panels and also
- 43:23Speaker 4: make sure that their results are accurate and reliable. So,
- 43:28Speaker 4: could you elaborate on how you've seen laboratories partner with
- 43:33Speaker 4: academic institutions and maybe a success story.
- 43:37Speaker 7: Yeah, I mean, so, you know, we sort of touched
- 43:40Speaker 7: on in a bit if they're you know, say, there
- 43:42Speaker 7: there's something new that requires additional evidence. What we hear
- 43:45Speaker 7: a lot, I think from laboratories that are trying to
- 43:46Speaker 7: get into the field is well, if you don't pay
- 43:49Speaker 7: me now to develop my service, how am I going
- 43:54Speaker 7: to survive you know, while I'm waiting to develop that
- 43:58Speaker 7: service into validate that service. Uh. And so it's kind
- 44:02Speaker 7: of a chicken and egg type of question, right that
- 44:04Speaker 7: you you know, you want to get into the lab,
- 44:06Speaker 7: you need to get the money to support the validation
- 44:09Speaker 7: and the development, but yet we're not going to reimburse
- 44:13Speaker 7: your service until there is a policy, until the evidence
- 44:18Speaker 7: has been developed. So for conditions that you know may
- 44:23Speaker 7: not be uh you know, on a sea Pick guideline
- 44:26Speaker 7: or an f D a guideline, we are I would
- 44:31Speaker 7: suggest right partnering with physicians or academics who are doing
- 44:37Speaker 7: the research to help develop that evidence for a particular
- 44:41Speaker 7: gene drug relationship. And that way the evidence is there,
- 44:46Speaker 7: that evidence gets published, that that evidence is reviewed by
- 44:52Speaker 7: folks like Cepick or the FDA, and we actually have
- 44:55Speaker 7: things to point back to when laboratories submit their their services,
- 45:00Speaker 7: so you can say this is guideline space or this
- 45:02Speaker 7: is not guideline space. An example that we see all
- 45:06Speaker 7: the time is mthfr. Folks keep putting mthfr on their panels,
- 45:13Speaker 7: yet there's actually guidelines out there about not to publish mthfr.
- 45:19Speaker 7: So that's an example.
- 45:20Speaker 6: Thanks Megan for joining me on this episode.
- 45:23Speaker 4: We covered a lot of ground today, including how laboratories
- 45:27Speaker 4: may overcome the challenges they face earning Moldix coverage and
- 45:30Speaker 4: reimbursement for their clinical pharmacogenemics tests. Please share any final
- 45:36Speaker 4: thoughts and advice you have with our audience, such as
- 45:38Speaker 4: how labs can stay informed about Muldix's PGX coverage and
- 45:43Speaker 4: reimbursement policies and how they might contact you.
- 45:47Speaker 10: Sure, So, my.
- 45:48Speaker 7: Biggest piece of advice is when you start opening up
- 45:51Speaker 7: the documents and looking at the information that we require.
- 45:55Speaker 7: If you don't understand what to put in a box
- 45:59Speaker 7: or in a line or on a piece of paper,
- 46:01Speaker 7: just reach out to us we can. Our team can
- 46:05Speaker 7: be contacted at DEX customer support at palmetogba dot com.
- 46:11Speaker 7: We also have technical assessments at palmetogba dot com and
- 46:17Speaker 7: Moldex at palmetogba dot com. All of these email addresses
- 46:21Speaker 7: can be found on our dex website or a Moldex
- 46:25Speaker 7: website which you can just google. But I can't stress
- 46:28Speaker 7: enough that if you're not sure, if you're just getting
- 46:31Speaker 7: into it, if something doesn't make sense, just shoot us
- 46:34Speaker 7: an email, shoot us a question. Our team is really
- 46:37Speaker 7: responsive and we try to get back to people right away.
- 46:40Speaker 7: So don't ever guess and you think you know what
- 46:44Speaker 7: we expect, et cetera. Always make sure you have your
- 46:48Speaker 7: validation documentation ready to go. We assume that if you're
- 46:51Speaker 7: going to be testing patients, that your test has been
- 46:54Speaker 7: fully vetted and validated within your laboratory, and you should
- 46:57Speaker 7: be able to get those documents to us right away
- 47:00Speaker 7: and if not, you shouldn't be testing patients. So if
- 47:05Speaker 7: anybody ever has any questions, like I said, just ask.
- 47:09Speaker 7: That is the biggest piece of advice that I can
- 47:10Speaker 7: give everybody is you can never ask too many questions
- 47:13Speaker 7: about what you should and should not be doing to
- 47:15Speaker 7: be able to submit technical assessment information to the MULTIX
- 47:20Speaker 7: program and get a ecode. So we're always up for questions.
- 47:26Speaker 6: And I can absolutely attest to.
- 47:28Speaker 4: How open you guys or to questions and you make
- 47:32Speaker 4: yourself available and you're very patient.
- 47:35Speaker 6: You're very patient in your answer, so we really appreciate that.
- 47:39Speaker 4: So wrapping up, we would be remiss if we didn't
- 47:42Speaker 4: thank our audience for tuning in, because without our faithful listeners,
- 47:46Speaker 4: we wouldn't have such a successful podcast.
- 47:48Speaker 6: And I mean for that, we're very grateful.
- 47:51Speaker 4: We do a lot of pg X in here on
- 47:53Speaker 4: the Precision Health and PGS podcast PGX Science, Clinical, Application
- 47:58Speaker 4: and Business, and we hope you've learned something today. You
- 48:02Speaker 4: can listen to all of our episodes on PGX FORRX
- 48:06Speaker 4: dot com or your preferred podcast platform such as Apple Podcasts, Podcasts, Spotify.
- 48:13Speaker 7: And podb.
- 48:15Speaker 4: While you're on the platform, please leave us a five
- 48:18Speaker 4: star review so our sponsors will continue to make this
- 48:21Speaker 4: podcast possible. We'd love to hear from you. What can
- 48:25Speaker 4: we teach you, What industry updates do you want to
- 48:28Speaker 4: learn about. Drop us a message on LinkedIn and let
- 48:31Speaker 4: us know so. Until next time, here's to precision health
- 48:35Speaker 4: and removing the trial and error from pharmacogenomics.